Eli Lilly vs. Viking Therapeutics: Wall Street’s Take on Growth Potential in Weight Loss Drug Market
The weight loss drug market, currently valued at $28 billion, is projected to surge to $95 billion by 2030. Eli Lilly (LLY) and Viking Therapeutics (VKTX) stand as key players, though their trajectories differ. Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, has already achieved blockbuster status, with demand outstripping supply for much of last year. Manufacturing investments and new dosage formats have since alleviated shortages.
Viking, while yet to commercialize a product, boasts promising phase 2 and phase 3 trial results for its candidates. Both stocks have delivered triple-digit returns over three years, though recent performance has been uneven. Wall Street now weighs which offers superior growth potential as the industry accelerates.
